ROIV.US Roivant Sciences Ltd

Healthcare Biotechnology USA Stocks
38.61 USD
Close of Nov 17, 2026
19.96 42.50
Market cap
USD 28.0B
P/E
-
P/B
7.12x
ROE
-19.0%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Sep 2026.

Is ROIV.US undervalued?

Graham number

The Graham number of Roivant Sciences Ltd cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Roivant Sciences Ltd fundamental analysis

No fundamental analysis for Roivant Sciences Ltd yet.

Roivant Sciences Ltd stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Roivant Sciences Ltd

Roivant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines and technologies. Its clinical product candidates include IMVT-1402, a fully human monoclonal antibody targeting FcRn in development across several IgG-mediated autoimmune indications; mosliciguat, an inhaled sGC activator in development for pulmonary hypertension associated with interstitial lung disease; neonatal fragment crystallizab…

Full company profile